Roche (OTCQX:RHHBY) (OTCQX:RHHBF) announced Wednesday that a Phase 3 trial for a high-dose version of its multiple sclerosis therapy Ocrevus (ocrelizumab) failed in a Phase 3 trial, sending the shares of rival MS drug developer TG Therapeutics (NASDAQ:TGTX) higher.
The